Clinical Trials Logo

Filter by:
NCT ID: NCT06263231 Recruiting - Sarcoma,Soft Tissue Clinical Trials

A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

INVINCIBLE-3
Start date: June 2024
Phase: Phase 3
Study type: Interventional

To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless contraindicated, and then a maximum of 1 additional regimen.

NCT ID: NCT06263114 Recruiting - Clinical trials for Liver Transplant; Complications

Correlation of Blood Gene Expression (TruGraf Liver) With Liver Biopsy in Pediatric Liver Transplant Recipients

Start date: January 1, 2024
Phase:
Study type: Observational

Liver transplant rejection is when the body's immune system attacks and damages the liver of a transplant recipient. Currently the best way to see if that is happening is with a liver biopsy. The purpose of this research study is to see if a simple blood test can diagnose if a transplanted liver is being rejected.

NCT ID: NCT06263023 Recruiting - Organ Preservation Clinical Trials

A Central Preservation and Assessment Service to Optimize Donor Kidney Allocation

OPTIMAL
Start date: April 19, 2024
Phase:
Study type: Observational

This is a study to collect information to assess if transporting hard-to-place (HTP) donor kidneys to a central preservation and assessment facility with dedicated organ assessment capabilities increases allocation success to transplant hospitals.

NCT ID: NCT06263010 Recruiting - Parkinson Disease Clinical Trials

Allopregnanolone as a Regenerative Treatment for Parkinson's Disease

Allo-PD
Start date: January 12, 2024
Phase: Phase 1
Study type: Interventional

The goal of this open-label, pilot clinical trial is to test allopregnanolone as a regenerative treatment in patients with Parkinson's disease (PD). The main questions this study aims to answer are: 1. Is a large-scale clinical trial testing how well it works in patients with PD feasible? 2. Is allopregnanolone safe and well-tolerated in patients with PD. 3. Can we see any signals of changes in imaging and clinical scales? Participants will receive a weekly infusion in their vein of allopregnanolone for a total of 12 weeks. There is no placebo so everyone receives allopregnanolone and "Open-label" means the study is not blinded so both the participant and investigators know the assigned treatment.

NCT ID: NCT06262880 Recruiting - Clinical trials for Intestinal Permeability

Dietary Supplementation on Gastrointestinal Barrier Function

Start date: February 6, 2024
Phase: N/A
Study type: Interventional

The purpose of the current study is to examine the effects of a dietary supplement containing plant derived phenolics at two different dose levels on parameters of gastrointestinal (GI) health in otherwise generally healthy adults with risk factors (high BMI and waist circumference) for increased GI permeability. The primary hypothesis is that supplementation with plant derived phenolics will improve gut health compared to placebo.

NCT ID: NCT06262607 Recruiting - Clinical trials for Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)

A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica

Start date: January 29, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of CLE-400 topical gel for the treatment of chronic pruritus in adult subjects with Notalgia Paresthetica (NP).

NCT ID: NCT06262516 Recruiting - Clinical trials for Urothelial Carcinoma

Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

Start date: May 17, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to conduct the first randomized-controlled trial to determine the oncologic efficacy of lymph node dissection in participants with upper tract urothelial cell carcinoma. The main questions it aims to answer are: - To determine oncologic outcomes, specifically 2-year recurrence-free survival - To determine other oncologic outcomes including treatment-free, cancer-specific and overall survival - To determine time to recurrence and recurrence patterns - To determine use of adjuvant therapies - To determine perioperative complications Participants will undergo nephroureterectomy with or without lymph node dissection. Researchers will compare these two groups to determine the oncologic efficacy of performing lymph node dissection.

NCT ID: NCT06262477 Recruiting - Healthy Volunteer Clinical Trials

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Start date: January 2, 2024
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to show equivalence in pharmacokinetics (PK) of BIIB800 and Actemra following SC administration of a single dose to healthy male participants. The secondary objective of the study is to evaluate PK over time, clinical safety, pharmacodynamic (PD) profiles and immunogenicity of BIIB800 and Actemra.

NCT ID: NCT06262451 Recruiting - Clinical trials for Fecal Microbiota Transplant

Fecal Microbiota Transplant National Registry

Start date: October 20, 2023
Phase:
Study type: Observational

A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness. Neonates will not be enrolled at any site for this study. The study data will derive from patient and donors past and present medical records, research records, and records about phone calls made as part of this research. The patient data will also be used from the records on visits.

NCT ID: NCT06262347 Recruiting - Pregnancy Related Clinical Trials

Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD

TOME
Start date: June 13, 2024
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate the ability of TOME to increase Medication for Opioid Use Disorder (MOUD) and opioid-overdose knowledge in pregnant and postpartum persons.